ARDX — ARDELYX, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1437402 ·
Last close
$3.74
Market Cap
$965.62M
52W High
$6.47
52W Low
$3.72
ADV30
4,212,668
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 120,877,000 | 115,118,000 | -12,425,000 | -16,721,000 | 575,894,000 | 97,191,000 | 426,881,000 |
| Mar 2026 | 94,473,000 | 89,662,000 | -32,793,000 | -37,605,000 | 504,507,000 | 31,209,000 | 355,885,000 |
| Dec 2025 | 125,215,000 | 114,366,000 | 5,099,000 | -407,000 | 501,604,000 | 67,999,000 | 334,655,000 |
| Sep 2025 | 110,329,000 | 106,347,000 | 4,668,000 | -969,000 | 486,170,000 | 42,715,000 | 331,890,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,320,000
Investing CF
$-34,067,000
Financing CF
$58,533,000
CapEx
$-599,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.22
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,001,265,000
Inventory
$25,858,000
Receivables
$100,352,000
ST Investments
$184,639,000
EBIT TTM
$-26,774,000
Pretax Income TTM
$-55,475,000
Interest Exp TTM
$28,701,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$450,894,016
EBITDA
$-32,106,000
Free Cash Flow
$20,468,000
Enterprise Value
$970,016,640
Total Cash
$281,830,016
Total Debt
$282,507,008
Shares Out
258,187,572
Trailing EPS
$-0.23
Book Value
$0.60
ROE
-38.6%
ROA
-4.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 407,320,000 | -40,977,000 | -61,599,000 | 501,604,000 | 334,655,000 | — | -42,483,000 |
| Dec 2024 | 333,615,000 | -27,950,000 | -39,136,000 | 435,754,000 | 262,465,000 | — | -44,809,000 |
| Dec 2023 | 124,456,000 | -63,276,000 | -66,067,000 | 297,579,000 | 130,763,000 | — | -89,717,000 |
| Dec 2022 | 52,158,000 | -63,759,000 | -67,207,000 | 190,066,000 | 91,737,000 | — | -70,044,000 |
TTM Snapshot
Revenues TTM
$98,241,000
NetIncome TTM
$-809,000
OpCashFlow TTM
$0
Assets (Latest)
$435,754,000
Forward EPS
$0.25
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $3.00 · spot: $3.74 · call volume: 1,197 · put volume: 18
Expected Move to 2027-01-15:
±$1.53
(40.91%) —
implied range
$2.21 –
$5.27
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMMX | Immix Biopharma, Inc. | $968.90M | $13.61 | — |
| ANNX | Annexon, Inc. | $959.27M | $5.06 | — |
| GERN | GERON CORP | $976.56M | $1.52 | — |
| PCRX | Pacira BioSciences, Inc. | $978.19M | $24.86 | — |
| DSGN | Design Therapeutics, Inc. | $953.12M | $15.23 | — |
News headlines (Yahoo Finance, 1h cache)
Ardelyx (ARDX) Cuts Guidance On Payer Hurdles As Fair Value Debate Heats Up
2026-08-22 18:08 · Yahoo
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript
2026-08-14 00:44 · Yahoo
Ardelyx (ARDX) Posts Record Revenue, Is The Stock Still 70% Undervalued?
2026-08-07 15:13 · Yahoo
Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics
2026-08-06 23:00 · Yahoo
Ardelyx Q2 Earnings Call Highlights
2026-08-06 22:04 · Yahoo
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 20:05 · Yahoo
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-23 12:01 · Yahoo
Claude AI Says Market is Ignoring Ardelyx (ARDX) Growth Catalysts
2026-07-20 19:18 · Yahoo
ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle
2026-06-26 21:14 · Yahoo
New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA Cliff
2026-07-29 14:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.